MiMedx Group, Inc. (MDXG)
NASDAQ: MDXG · Real-Time Price · USD
9.14
+0.02 (0.22%)
Jan 21, 2025, 4:00 PM EST - Market closed
MiMedx Group Revenue
MiMedx Group had revenue of $84.06M in the quarter ending September 30, 2024, with 2.87% growth. This brings the company's revenue in the last twelve months to $342.80M, up 10.93% year-over-year. In the year 2023, MiMedx Group had annual revenue of $321.48M with 20.03% growth.
Revenue (ttm)
$342.80M
Revenue Growth
+10.93%
P/S Ratio
3.74
Revenue / Employee
$383,021
Employees
895
Market Cap
1.34B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 321.48M | 53.64M | 20.03% |
| Dec 31, 2022 | 267.84M | 25.82M | 10.67% |
| Dec 31, 2021 | 242.02M | -6.22M | -2.50% |
| Dec 31, 2020 | 248.23M | -51.02M | -17.05% |
| Dec 31, 2019 | 299.26M | -59.86M | -16.67% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 87.70B |
| Merck & Co. | 63.17B |
| AbbVie | 55.53B |
| AstraZeneca | 51.21B |
| Novartis AG | 49.94B |
| Thermo Fisher Scientific | 42.37B |
| Abbott Laboratories | 41.22B |
MDXG News
- 2 months ago - MIMEDX's Advocacy to Rein in Runaway Medicare Spend for Skin Substitutes Has Yielded Significant Results with Planned Implementation of LCDs - GlobeNewsWire
- 2 months ago - MiMedx Group, Inc. (MDXG) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - MIMEDX Announces Third Quarter 2024 Operating and Financial Results - GlobeNewsWire
- 3 months ago - MIMEDX to Host Third Quarter 2024 Operating and Financial Results Conference Call on October 30 - GlobeNewsWire
- 3 months ago - MIMEDX Points to The New York Times Article on the Vast Benefits of Placental Tissue - GlobeNewsWire
- 4 months ago - MIMEDX Showcases Leading Allograft Portfolio and Its Latest Scientific and Clinical Evidence at SAWC Fall - GlobeNewsWire
- 4 months ago - EX-MiMEDX EMPLOYEES ALLEGE MiMEDX "PRESSURE[D] HEALTHCARE PROVIDERS TO TREAT WOUNDED VETERANS, DIABETICS, CHRONIC WOUND SUFFERERS, AND OTHER PATIENTS WITH MEDICALLY UNNECESSARY OR UNSUITABLE PRODUCTS" - PRNewsWire
- 4 months ago - THIRD DEFENDANT FIGHTS BACK AGAINST MiMEDX, CLAIMING 'DISREPUTABLE AND UNLAWFUL BUSINESS PRACTICES' - PRNewsWire